{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "It is a puzzling political season for George Gauthier. Although the major presidential candidates were identified months ago, Mr. Gauthier, a builder, has no idea whom he will vote for.", "headline": {"main": "Potential Voters Skeptical, Lacking Passion for Candidates", "kicker": "THE 2000 CAMPAIGN: THE ELECTORATE"}, "abstract": "Interviews in Evanston, Illinois, a critical swing-vote state, find voters studiously skeptical, awaiting answers and wary of campaign games politicians play; most seem to be sizing up presidential candidates as managers, stewards and respect-worthy leaders rather than as rallying, agenda-driven politicians; photos (M)", "print_page": "16", "word_count": 1742, "_id": "4fd225268eb7c8105d7ac06e", "snippet": "It is a puzzling political season for George Gauthier.    Although the major presidential candidates were identified months ago, Mr. Gauthier, a builder, has no idea whom he will vote for.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2000/07/28/us/2000-campaign-electorate-potential-voters-skeptical-lacking-passion-for.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "persons", "value": "GORE, AL"}, {"name": "glocations", "value": "ILLINOIS"}, {"name": "glocations", "value": "EVANSTON (ILL)"}, {"name": "subject", "value": "PUBLIC OPINION"}, {"name": "subject", "value": "ELECTION ISSUES"}, {"name": "subject", "value": "PRESIDENTIAL ELECTION OF 2000"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Pam", "lastname": "BELLUCK"}], "original": "By PAM BELLUCK"}, "document_type": "article", "pub_date": "2000-07-28T00:00:00Z", "section_name": "U.S."}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "In denouncing President Clinton's plan to extend Medicare coverage to prescription drugs, and in touting their own counterproposal, Republicans have rolled out the usual rhetoric. They excoriate the administration plan as a bureaucratic, ''one size fits all'' solution. They claim that their plan offers more choice. And for once their claims are absolutely right. The Republican plan does offer more choice. Unfortunately, this is one of those cases in which more choice is actually bad for everyone. In fact, by trying to give people more choices the Republican plan would end up denying them any choice at all.", "headline": {"main": "Reckonings; Prescription for Failure"}, "abstract": "Paul Krugman Op-Ed column holds Republican counterproposal to Pres Clinton's plan to extend Medicare coverage to prescription drugs is unworkable; holds private drug insurance for aged could be offered at reasonable price only if people had to commit to paying necessary premiums before they knew whether they would need costly drugs", "print_page": "23", "word_count": 716, "_id": "4fd2087e8eb7c8105d773894", "snippet": "In denouncing President Clinton's plan to extend Medicare coverage to prescription drugs, and in touting their own counterproposal, Republicans have rolled out the usual rhetoric. They excoriate the administration plan as a bureaucratic, ''one size...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2000/07/26/opinion/reckonings-prescription-for-failure.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "CLINTON, BILL"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "HEALTH INSURANCE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Paul", "rank": 1, "lastname": "KRUGMAN"}], "original": "By PAUL KRUGMAN"}, "document_type": "article", "pub_date": "2000-07-26T00:00:00Z", "section_name": "Health; Opinion"}, {"type_of_material": "Series", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The stakes were high on Feb. 2, 1998, when Zenith Goldline Pharmaceuticals and Abbott Laboratories squared off here in patent court. For three years, the companies had been fighting about whether Zenith could market a generic version of Hytrin, Abbott's $500-million-a-year drug for high blood pressure and prostate enlargement. Now a federal appeals judge would hear them out. ''Abbott makes a million dollars a day for every day it keeps us off the market,'' Bill Mentlik, Zenith's lawyer, argued in court. Without a cheaper generic, he warned, ''the public is losing.''", "headline": {"main": "Keeping Down the Competition; How Companies Stall Generics And Keep Themselves Healthy"}, "abstract": "Medicine Merchants, article in series examining marketing and business practices in pharmaceutical industry, describes how companies stall generic versions of their drugs; Congress passed law in 1984 intended to keep drug prices down by speeding up entry of generic drugs; Rep Henry A Waxman, author of bill, says pharmaceutical companies, through different business arrangements, have made reverse happen; in fact, efforts to extend profitable drug's monopoly, as much as pursuit of scientific discoveries, drive decisions in one of world's most lucrative, and secretive, industries; detailed description of Abbott Laboratories' efforts to protect patent on its drug, Hytrin, against companies seeking to offer generic version; that effort has spawned 13 private antitrust suits against Abbott, and others filed by health maintenance organizations, pharmacies and drug wholesalers; photos; graphs (L)", "print_page": "1", "word_count": 5326, "_id": "4fd2251e8eb7c8105d7abab6", "snippet": "The stakes were high on Feb. 2, 1998, when Zenith Goldline Pharmaceuticals and Abbott Laboratories squared off here in patent court. For three years, the companies had been fighting about whether Zenith could market a generic version of Hytrin,...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2000/07/23/us/keeping-down-competition-companies-stall-generics-keep-themselves-healthy.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "WAXMAN, HENRY A"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "ABBOTT LABORATORIES INC"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "HEALTH MAINTENANCE ORGANIZATIONS AND MANAGED CARE"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "ANTITRUST ACTIONS AND LAWS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "INVENTIONS AND PATENTS"}], "byline": {"person": [{"firstname": "Sheryl", "middlename": "Gay", "lastname": "STOLBERG", "rank": 1, "role": "reported", "organization": ""}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Jeff", "lastname": "GERTH"}], "original": "By SHERYL GAY STOLBERG and JEFF GERTH"}, "document_type": "article", "pub_date": "2000-07-23T00:00:00Z", "section_name": "Technology; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Pharmaceuticals are a risky, but lucrative, business. Drug companies turn scientific advances into life-saving medicines that can generate millions of dollars in sales each day, but the process takes time -- an average of 12 to 15 years -- and money. Through a recent wave of mergers and acquisitions, the prescription drug industry is increasingly global. But the companies earn most of their profits, and do most of their basic research, in the United States, the last drug market free of price restraints. The industry consistently ranks as the most profitable among Fortune 500 companies.", "headline": {"main": "In a Drug's Journey to Market, Discovery Is Just the First of Many Steps"}, "abstract": "Article describes long process by which drug comes to market: from discovery, to clinical testing, to getting regulators' approval, to patenting, to generic competition; graphs (L)", "print_page": "15", "word_count": 1684, "_id": "4fd217848eb7c8105d792d36", "snippet": "Pharmaceuticals are a risky, but lucrative, business. Drug companies turn scientific advances into life-saving medicines that can generate millions of dollars in sales each day, but the process takes time -- an average of 12 to 15 years -- and money....", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2000/07/23/us/in-a-drug-s-journey-to-market-discovery-is-just-the-first-of-many-steps.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "INVENTIONS AND PATENTS"}], "byline": {"person": [{"firstname": "Sheryl", "middlename": "Gay", "lastname": "STOLBERG", "rank": 1, "role": "reported", "organization": ""}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Jeff", "lastname": "GERTH"}], "original": "By SHERYL GAY STOLBERG and JEFF GERTH"}, "document_type": "article", "pub_date": "2000-07-23T00:00:00Z", "section_name": "Technology; Health; U.S."}], "meta": {"hits": 4, "offset": 0, "time": 35}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}